Your Article Summary
See Latest ArticlesManagement of altered hydrocortisone pharmacokinetics in a boy with congenital adrenal hyperplasia using a continuous subcutaneous hydrocortisone infusion
Journal of Clinical Endocrinology and Metabolism, 07/01/09
Hindmarsh PC et al. - CSHI may prove a valuable adjunct to therapy for CAH particularly in patients requiring high doses or oral hydrocortisone and in those with abnormal hydrocortisone pharmacokinetics.
Related Articles
Nonclassic Lipoid Congenital Adrenal Hyperplasia Masquerading as Familial Glucocorticoid Deficiency
Journal of Clinical Endocrinology and Metabolism, 10/12/09
Relevance Score: 68%
Mutational Characterization of Steroid 21-Hydroxylase Gene in Portuguese patients with Congenital Adrenal Hyperplasia
Experimental and Clinical Endocrinology & Diabetes, 11/02/09
Relevance Score: 67%
Varied Presentation of Congenital Adrenal Hyperplasia with 21 (OH) Deficiency
Journal of Anaesthesiology Clinical Pharmacology, 10/19/09
Relevance Score: 67%
Classical Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency in Croatia between 1995 and 2006
Hormone Research, 10/27/09
Relevance Score: 66%
Evaluation of Adrenomedullary Function in Patients with Congenital Adrenal Hyperplasia
Hormone Research, 10/23/09
Relevance Score: 66%
Today in Pharmacokinetics...keeping you current
Receive free subspecialty "5-minute updates" via email
Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study
Annals of Oncology, 12/04/09
Does co-administration of paroxetine change oxycodone analgesia: An interaction study in chronic pain patients
Scandinavian Journal of Pain, 12/04/09
Clinical Pharmacokinetics of the BCR–ABL Tyrosine Kinase Inhibitor Nilotinib
Clinical Pharmacology & Therapeutics, 12/03/09